Targeted Combination Therapy Triggers Cell Death in Mouse Models of Metastatic Cancer

Wednesday, April 30, 2008 - 13:55 in Health & Medicine

A combination of two targeted drugs--one that blocks protein breakdown and one that activates the programmed cell death pathway--reduces the number of tumor metastases in mouse models of kidney and breast cancer. The combination also prolonged overall survival in mice with kidney cancer. Bortezomib blocks the activity of the proteasome, an enzyme complex which degrades misfolded or unwanted proteins. Bortezomib has been approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, but its activity against solid tumors is still being tested.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net